Anti-Mouse CD289 (TLR9) FITC

Grouped product items
SizePrice Qty
25 ug
$130.00
100 ug
$340.00

Additional M9.D6 Formats

Cat.No.FormatStarting From
31912-50FITC$ 130.00
Catalog Number : 31912-50

description

The M9.D6 monoclonal antibody specifically reacts with mouse CD289 also known as toll-like receptor 9 (TLR9). CD289 is involved in the activation of innate immunity, in acquired immune responses, and autoimmune diseases. It is involved in the immune system’s response to unmethylated CpG dinucleotide sequences such as those found in bacterial, viral, or synthetic DNA. CD289 assists in pathogen recognition and is expressed by subtypes of dendritic cells and B cells.

Additional Information

Clone:
M9.D6
Format:
FITC
Applications:
FC
Reactivity:
Mouse
Isotype:
Rat IgG2a
Research Interest:Innate Immunity
Cell Type:Macrophage / Monocyte, Dendritic Cells
Application:FC
Clone:M9.D6
Preparation:
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:

Kubo, T., Uchida, Y., Watanabe, Y., Abe, M., Nakamura, A., Ono, M., ... & Takai, T. (2009). Augmented TLR9-induced Btk activation in PIR-B–deficient B-1 cells provokes excessive autoantibody production and autoimmunity. The Journal of experimental medicine206(9), 1971-1982.

Fukata, M., Breglio, K., Chen, A., Vamadevan, A. S., Goo, T., Hsu, D., ... & Abreu, M. T. (2008). The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease.The Journal of Immunology180(3), 1886-1894.

Miranda-Hernandez, S., Gerlach, N., Fletcher, J. M., Biros, E., Mack, M., Körner, H., & Baxter, A. G. (2011). Role for MyD88, TLR2 and TLR9 but not TLR1, TLR4 or TLR6 in experimental autoimmune encephalomyelitis. The Journal of Immunology187(2), 791-804.

© BioGems International, Inc. All rights reserved.